Kymera Therapeutics KYMR Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$311.35M-39.1% | -$223.86M-52.3% | -$146.96M+5.1% | -$154.81M-54.5% | ||
| $8.31M+12.7% | $7.37M+107% | $3.57M+19.8% | $2.98M+24.2% | ||
| $59.9M+8.9% | $55.01M+27.6% | $43.12M+21.5% | $35.48M+42.1% | ||
| $3.86M— | —— | $0— | $0— | ||
| -$1.97M-543% | -$307K-115% | $2.04M— | —— | ||
| —— | —— | —— | $4.52M-64.1% | ||
| $7.43M— | —— | -$909K-191% | $998K— | ||
| —— | —— | —— | —— | ||
| —— | -$41.08M— | —— | -$37.77M+45.5% | ||
| -$232.89M-19.7% | -$194.5M-75.4% | -$110.87M+27.6% | -$153.09M-18.7% | ||
| $1.45M-88.9% | $13.03M-62.2% | $34.48M+1,116% | $2.84M+77.6% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| -$521.06M— | —— | $139.89M— | —— | ||
| $0— | —— | $0— | $0-100% | ||
| $1.49M-5.2% | $1.58M— | —— | $1.13M+33.1% | ||
| $990.71M+62.7% | $608.85M+13,744% | $4.4M-97.1% | $153M-38.9% | ||
| $236.76M+2,205% | $10.27M-75.1% | $41.25M— | —— | ||
| $312K+51.5% | $206K+27.2% | $162K-9.5% | $179K+13.3% | ||
| $3.86M-21.7% | $4.93M— | $0— | —— | ||
| —— | -$2.82M— | —— | —— | ||
| -$5.04M— | —— | $18.58M+1,951% | -$1M+1.1% | ||
| -$2.67M-4.9% | -$2.54M+47.0% | -$4.8M-828% | -$517K-23.4% | ||
| $18K+106% | -$310K-1,007% | -$28K-111% | $257K+199% | ||
| —— | —— | —— | $992K— | ||
| —— | —— | —— | —— | ||
| -$656.23M— | $0— | $0— | —— | ||
| $61.62M+423% | $11.79M+312% | $2.86M— | —— | ||
| —— | —— | $4.06M— | —— | ||
| $1.03M-62.5% | $2.74M— | $0-100% | $1.51M-21.5% | ||
| -$234.34M-13.0% | -$207.34M-51.0% | -$137.31M+11.9% | -$155.92M-19.4% | ||
| -$234.34M-13.0% | -$207.34M-51.0% | -$137.31M+11.9% | -$155.92M-19.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Kymera Therapeutics generate?
- Kymera Therapeutics (KYMR) generated -$242.6M in operating cash flow over the trailing twelve months.
- What is Kymera Therapeutics's free cash flow?
- After $1.4M of capital expenditures, Kymera Therapeutics's free cash flow was -$244.0M over the trailing twelve months, down 1.7% year over year.
- Where does Kymera Therapeutics's cash flow data come from?
- Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
